IMV : IMV Inc Stock Profile

Last Updated: 3/12/2024 0:47:16

IMV Inc trades with the ticker IMV on the TSX and is in the Biotechnology industry.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Looking to invest in IMV Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.

IMV.TO Stock Price and Key Stats

ETF Key Stats

Exchange: TSX

Market Cap : $13.117MM

PE Ratio:

Price: 4815.5 (Updated: 3/12/2024 0:47:16)

IMV Inc (IMV) vs Competitors in Biotechnology

Lets see how IMV.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:

Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, Intellipharmaceutics International Inc


Biotechnology Industry Comparisons

Company Market Cap ($MM) P/E Ratio EV/EBITDA Dividend Yield
Aeterna Zentaris Inc (AEZS) $12.674 N/A 1.709 N/A%
Aptose Biosciences Inc (APS) $33.927 N/A -0.231 N/A%
BELLUS Health Inc (BLU) $2,470.298 N/A -16.428 0.0%
Fennec Pharmaceuticals Inc (FRX) $352.565 N/A -21.793 N/A%
IMV Inc (IMV) $13.117 N/A -0.843 0.0%

EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield  

Comparisons within Biotechnology

  • IMV Inc (IMV) vs Aeterna Zentaris Inc (AEZS)
    • IMV has higher EPS (-6.11 vs -6.47). IMV provides dividends, while AEZS does not. AEZS and IMV both have P/E’s under 0.
  • IMV Inc (IMV) vs Aptose Biosciences Inc (APS)
    • IMV has higher EPS (-6.11 vs -10.45). IMV provides dividends, while APS does not. APS and IMV both have P/E’s under 0.
  • IMV Inc (IMV) vs BELLUS Health Inc (BLU)
    • BLU has higher EPS (-0.96 vs -6.11). BLU has higher dividend yield (0.0% vs 0.0%). BLU and IMV both have P/E’s under 0.
  • IMV Inc (IMV) vs Fennec Pharmaceuticals Inc (FRX)
    • FRX has higher EPS (-1.01 vs -6.11). IMV provides dividends, while FRX does not. FRX and IMV both have P/E’s under 0.
  • IMV Inc (IMV) vs Intellipharmaceutics International Inc (IPCI)
    • IPCI has higher EPS (-0.12 vs -6.11). IMV provides dividends, while IPCI does not. IPCI and IMV both have P/E’s under 0.

Our Recommendation: Review
May not stand out on key metrics or lacks sufficient data for a strong recommendation.

How to Buy IMV stock on the TSX

You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:

ImageProduct TitleFeaturesPrice
Editor's Choice
Wealthsimple Trade

Wealthsimple Trade

  • ETF buys and sells have $0 trading fees
  • Desktop and mobile trading
  • Reputable Brand
  • Beautiful Design
Get $25 Signup Bonus
Reliable Pick


  • ETF buys have $0 trading fees
  • Desktop and mobile trading
  • Most types of accounts available
Get $50 Free Stock Trades
Photo of author
Author Bio - Qayyum Rajan is a CFA Charterholder with 10+ years of finance experience and the co-creator of He has previously worked as a portfolio manager at RBC Dominion Securities and other roles at asset managers like Sentry Investments. He then started building websites and fintech apps to bring finance to everyone.

Check Out These Posts:

Leave a Comment